Trial Profile
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, ACTIVE- AND PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP STUDY OF THE ANALGESIC EFFECTS OF TANEZUMAB IN ADULT PATIENTS WITH CHRONIC LOW BACK PAIN
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Tanezumab (Primary) ; Naproxen
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 22 Dec 2022 Results of meta analysis (n=3414 from 3 studies NCT00584870,NCT00876187 and NCT02528253) assessing Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain published in the Clinical Neuropharmacology
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 22 Jul 2010 Planned end date changed from Jul 2010 to Aug 2010 as reported by ClinicalTrials.gov.